The IgV domain of the poliovirus receptor alone is immunosuppressive and binds to its receptors with comparable affinity

PVR (poliovirus receptor) functions as a ligand that signals through TIGIT and CD96 to induce suppression of T-cell and NK-cell responses. Alternatively, PVR binds to CD226, resulting in a co-stimulatory signal. To date, TIGIT antibody antagonists have been developed to restore immune functions and allow PVR to signal though CD226 in the context of cancer immunotherapy. Due to PVR receptor heterogeneity, agonizing either of these pathways with a recombinant form of the PVR extracellular domain represents a therapeutic strategy for either immunosuppression or activation. Here, we developed a minimal murine PVR-Fc fusion construct, consisting of only the IgV domain of PVR (vdPVR-Fc), and assessed its ability to dampen inflammatory responses in a murine model of psoriasis. vdPVR-Fc and PVR-Fc containing the full-length extracellular domain bound to TIGIT, CD96 and CD226 with similar low nanomolar affinities as defined by surface plasmon resonance. vdPVR-Fc was also able to suppress the in-vitro proliferation of murine CD4⁺ and CD8⁺ T-cells in mixed splenocyte cultures. Importantly, vdPVR-Fc delayed the onset, and reduced inflammatory responses (scaling and thickness) in a murine model of psoriasis. Collectively, our results suggest that the minimal IgV domain of PVR is sufficient to dampen immune responses in-vitro and attenuate symptoms of psoriasis in-vivo.

Agonistic nanobodies and antibodies to human VISTA

The V-domain Ig Suppressor of T-cell Activation (VISTA) is an immune checkpoint regulator that suppresses immune responses and is readily expressed on human and murine myeloid cells and T cells. This immunosuppressive pathway can be activated using VISTA agonists. Here, we report the development of murine anti-human VISTA (anti-hVISTA) monoclonal antibodies (mAbs), anti-hVISTA nanobodies (Nbs), and cross-reactive rat anti-murine/human VISTA (anti-hmVISTA) mAbs. All mAbs and Nbs generated bound to VISTA (human and/or murine) with dissociation constants in the sub-nanomolar or low nanomolar range. Competition analysis revealed that the selected Nbs bound the same or a nearby epitope(s) as the human VISTA-specific mAbs. However, the cross-reactive mAbs only partially competed with Nbs for binding to hVISTA. All mAbs and one Nb (hVISTANb7) were able to strongly detect VISTA expression on primary human monocytes. Importantly, the murine anti-hVISTA mAbs 7E12 and 7G5 displayed strong agonistic activity in human peripheral blood mononuclear cell cultures, while Nb7 and rat anti-hmVISTA mAbs 3C3, 7C6, 7C7, and 7G1 also behaved as hVISTA agonists, albeit to a lesser extent. Cross-reactive mAbs 7C7 and 7G1 further displayed agonistic potential in murine splenocyte assays. Importantly, mAb 7G1 significantly reduced inflammation associated with the murine model of imiquimod-induced psoriasis. These agonistic VISTA mAbs may represent therapeutic leads to treat inflammatory disorders.

A soluble activator that favors the ex vivo expansion of CD8+CD27+ T cells

Adoptive cell therapy involves the infusion of tumor-reactive T cells into patients with cancer to provide antitumor immunity. The ex vivo expansion and differentiation of such T cells are key parameters that affect their therapeutic potential. Human T cells are presently expanded in culture through the use of anti-CD3 and anti-CD28 mAbs immobilized on beads, expressed on cells, or assembled in the context of soluble antibody complexes. Here we report the design of a small, bispecific single-chain variable fragment construct agonizing both CD3 and CD28 pathways. This soluble T cell expansion protein, termed T-CEP, activates, expands, and differentiates human T cells ex vivo at concentrations in the femtomolar range. Importantly, T-CEP promotes the preferential growth of human CD8⁺ T cells over the course of 12 days in comparison with methods involving immobilized anti-CD3 mAb/soluble anti-CD28 mAb or soluble anti-CD3/CD28 mAb complexes. The differentiation profile of the resulting human T cell population is also singularly affected by T-CEP, favoring the expansion of a preferred CD8⁺CD27⁺ T cell phenotype. The activity profile of T-CEP on human T cells ex vivo suggests its use in generating human T cell populations that are more suited for adoptive cell therapy.

A bispecific protein construct is described that rapidly expands primary human T cell populations ex vivo at femtomolar concentrations with desirable phenotypic properties for adoptive cell therapy.

A powerful ICOS agonist that enhances anti-tumor immune responses restored by immune checkpoint inhibitors

The Inducible T cell Costimulator (ICOS, CD278) is a receptor in the CD28 family of B7-binding proteins expressed mostly by activated T cells. Upon binding to its ligand ICOS-L expressed on APCs,T cells are further activated by ICOS, resulting in their expansion and production of effector cytokines. Clinical data in patients treated with anti-CTLA-4 or anti-PD-1 mAbs have shown that ICOShiT cells correlated with an increased treatment response in these patients. Here, we report the design of a high avidity pentavalent form of the human ICOS-L extracellular domain fused to a short α-helical peptide from the human cartilage oligomeric matrix protein (COMP). This ICOS agonist, termed ICOS-L.COMP, spontaneously assembles into stable pentamers, binds tightly to both human and murine ICOS (SPR; Kd<10 nM) and co-stimulates (with anti CD3 mAb) the proliferation and cytokine release of both murine and human CD4+ and CD8+ T cells when added as a soluble factor (unlike ICOS-L.Fc). Soluble ICOS-L.COMP also phosphorylates Akt in activated T cells and enhances anti-tumor immune responses in tumor-bearing mice [murine MC38 or CT26 tumors] treated with either anti-murine PD-1 or anti-murine CTLA-4 mAb. Impressively, most mice treated with ICOS-L.COMP combined with an immune checkpoint inhibitor were either cured or displayed a stable tumor burden in contrast to checkpoint monotherapies (delayed tumor progression) or when ICOS-L.COMP was given as a monotherapy (comparable to no treatment). Importantly, ICOS-L.COMP lacks a Fc domain thus eliminating Fc-associated off-target adverse effects. In summary, our results suggest that ICOS-L.COMP represents a new and powerful biologic to be used in combination with existing immune checkpoint inhibitors.

MRI features of presumed normal palatine tonsils in dogs

OBJECTIVE

To describe the MRI characteristics of normal palatine tonsils in dogs.

MATERIALS AND METHODS

Retrospective study of 95 dogs with presumed normal tonsils. Tonsillar margination, shape and signal intensity in pre- and postcontrast studies were assessed and the cross-sectional area was measured at the point of maximal size on transverse images.

RESULTS

In all cases the tonsils were located with their largest transverse cross-section at the level of the temporomandibular joints. Their margins were well-defined in all dogs; in 57 (60%) the borders were smooth and in 38 (40%) slightly irregular. The majority (96%) of the tonsils were rounded to oval in cross-section and the remainder were elongated. All tonsils were hyperintense to the medial pterygoid muscles in T1-weighted, T2-weighted, FLAIR and T2* gradient echo images and they showed either homogeneous (53%) or heterogeneous (47%) signal intensity. Contrast enhancement was marked (65%) or moderate (33%) in the majority of animals. Median tonsillar cross-sectional area was approximately 29 mm² (90% confidence interval: 10.0 to 64.4 mm² ). There was significant positive correlation between bodyweight and tonsillar cross-sectional area and a weak negative correlation between age and tonsillar cross-sectional area.

CLINICAL SIGNIFICANCE

MRI is of value in assessing normal palatine tonsils in dogs. This study could be used as a baseline for the investigation of the value of MRI in assessment of tonsillar disease in dogs.

Novel half-life extended anti-MIF nanobodies protect against endotoxic shock

Sepsis-leading to septic shock-is the leading cause of death in intensive care units. The systemic inflammatory response to infection, which is initiated by activated myeloid cells, plays a key role in the lethal outcome. Macrophage migration inhibitory factor (MIF) is an upstream immunoregulatory mediator, released by myeloid cells, that underlies a common genetic susceptibility to different infections and septic shock. Accordingly, strategies that are aimed at inhibiting the action of MIF have therapeutic potential. Here, we report the isolation and characterization of tailorable, small, affinity-matured nanobodies (Nbs; single-domain antigen-binding fragments derived from camelid heavy-chain Abs) directed against MIF. Of importance, these bioengineered Nbs bind both human and mouse MIFs with nanomolar affinity. NbE5 and NbE10 inhibit key MIF functions that can exacerbate septic shock, such as the tautomerase activity of MIF (by blocking catalytic pocket residues that are critical for MIF's conformation and receptor binding), the TNF-inducing potential, and the ability of MIF to antagonize glucocorticoid action. A lead NbE10, tailored to be a multivalent, half-life extended construct (NbE10-NbAlb8-NbE10), attenuated lethality in murine endotoxemia when administered via single injection, either prophylactically or therapeutically. Hence, Nbs, with their structural and pharmacologic advantages over currently available inhibitors, may be an effective, novel approach to interfere with the action of MIF in septic shock and other conditions of inflammatory end-organ damage.-Sparkes, A., De Baetselier, P., Brys, L., Cabrito, I., Sterckx, Y. G.-J., Schoonooghe, S., Muyldermans, S., Raes, G., Bucala, R., Vanlandschoot, P., Van Ginderachter, J. A., Stijlemans, B. Novel half-life extended anti-MIF nanobodies protect against endotoxic shock.

Molecular Imaging with Kupffer Cell-Targeting Nanobodies for Diagnosis and Prognosis in Mouse Models of Liver Pathogenesis

PURPOSE

Kupffer cells (KCs), the liver resident macrophages, are important mediators of tissue homeostasis and pathogen clearance. However, depending on the inflammatory stimuli, KCs have been involved in divergent hepato-protective or hepato-destructive immune responses. The versatility of KCs in response to environmental triggers, in combination with the specific biomarkers they express, make these macrophages attractive in vivo targets for non-invasive monitoring of liver inflammation or pathogenicity. This study aims to determine whether V-set and Ig domain-containing 4 (Vsig4) and C-type lectin domain family (Clec) 4, member F (Clec4F) can be used as imaging biomarkers for non-invasive monitoring of KCs during distinct liver inflammation models.

PROCEDURE

Flow cytometry (FACS), immuno-histochemistry (IHC), and single-photon emission computed tomography (SPECT) with Tc-99m labeled anti-Vsig4 or anti-Clec4F nanobodies (Nbs) was performed to evaluate in mice KC dynamics in concanavalin A (ConA)-induced hepatitis and in non-alcoholic steatohepatitis induced via methionine choline deficiency (MCD).

RESULTS

In homeostatic mice, Nbs targeting Clec4F were found to accumulate and co-localize with Vsig4-targeting Nbs only in the liver. Upon induction of acute hepatitis using ConA, down-regulation of the in vivo Nb imaging signal was observed, reflecting reduction in KC numbers as confirmed by FACS and IHC. On the other hand, induction of steatohepatitis resulted in higher signals in the liver corresponding to higher density of KCs. The Nb-imaging signals returned to normal levels after resolution of the investigated liver diseases.

CONCLUSIONS

Anti-Clec4F and anti-Vsig4 Nbs targeting KCs as molecular imaging biomarkers could allow non-invasive monitoring/staging of liver pathogenesis.

VISTA.COMP - an engineered checkpoint receptor agonist that potently suppresses T cell-mediated immune responses

V-domain immunoglobulin suppressor of T cell activation (VISTA) is a recently discovered immune checkpoint ligand that functions to suppress T cell activity. The therapeutic potential of activating this immune checkpoint pathway to reduce inflammatory responses remains untapped, largely due to the inability to derive agonists targeting its unknown receptor. A dimeric construct of the IgV domain of VISTA (VISTA-Fc) was shown to suppress the activation of T cells in vitro. However, this effect required its immobilization on a solid surface, suggesting that VISTA-Fc may display limited efficacy as a VISTA-receptor agonist in vivo. Herein, we have designed a stable pentameric VISTA construct (VISTA.COMP) by genetically fusing its IgV domain to the pentamerization domain from the cartilage oligomeric matrix protein (COMP). In contrast to VISTA-Fc, VISTA.COMP does not require immobilization to inhibit the proliferation of CD4+ T cells undergoing polyclonal activation. Furthermore, we show that VISTA.COMP, but not VISTA-Fc, functions as an immunosuppressive agonist in vivo capable of prolonging the survival of skin allografts in a mouse transplant model as well as rescuing mice from acute concanavalin-A-induced hepatitis. Collectively, we believe our data demonstrate that VISTA.COMP is a checkpoint receptor agonist and the first agent to our knowledge targeting the putative VISTA-receptor to suppress T cell-mediated immune responses.

Reprint of: The non-mammalian MIF superfamily

Macrophage migration inhibitory factor (MIF) was first described as a cytokine 50 years ago, and emerged in mammals as a pleiotropic protein with pro-inflammatory, chemotactic, and growth-promoting activities. In addition, MIF has gained substantial attention as a pivotal upstream mediator of innate and adaptive immune responses and with pathologic roles in several diseases. Of less importance in mammals is an intrinsic but non-physiologic enzymatic activity that points to MIF's evolution from an ancient defense molecule. Therefore, it is not surprising that mif-like genes also have been found across a range of different organisms including bacteria, plants, protozoa, helminths, molluscs, arthropods, fish, amphibians and birds. While Genebank analysis identifying mif-like genes across species is extensive, contained herein is an overview of the non-mammalian MIF-like proteins that have been most well studied experimentally. For many of these organisms, MIF contributes to an innate defense system or plays a role in development. For parasitic organisms however, MIF appears to function as a virulence factor aiding in the establishment or persistence of infection by modulating the host immune response. Consequently, a combined targeting of both parasitic and host MIF could lead to more effective treatment strategies for parasitic diseases of socioeconomic importance.

The non-mammalian MIF superfamily

Macrophage migration inhibitory factor (MIF) was first described as a cytokine 50 years ago, and emerged in mammals as a pleiotropic protein with pro-inflammatory, chemotactic, and growth-promoting activities. In addition, MIF has gained substantial attention as a pivotal upstream mediator of innate and adaptive immune responses and with pathologic roles in several diseases. Of less importance in mammals is an intrinsic but non-physiologic enzymatic activity that points to MIF's evolution from an ancient defense molecule. Therefore, it is not surprising that mif-like genes also have been found across a range of different organisms including bacteria, plants, ‎protozoa, helminths, molluscs, arthropods, fish, amphibians and birds. While Genebank analysis identifying mif-like genes across species is extensive, contained herein is an overview of the non-mammalian MIF-like proteins that have been most well studied experimentally. For many of these organisms, MIF contributes to an innate defense system or plays a role in development. For parasitic organisms however, MIF appears to function as a virulence factor aiding in the establishment or persistence of infection by modulating the host immune response. Consequently, a combined targeting of both parasitic and host MIF could lead to more effective treatment strategies for parasitic diseases of socioeconomic importance.

Measurement of the [Formula: see text] production cross-section in proton-proton collisions via the decay [Formula: see text]

The production of the [Formula: see text] state in proton-proton collisions is probed via its decay to the [Formula: see text] final state with the LHCb detector, in the rapidity range [Formula: see text] and in the meson transverse-momentum range [Formula: see text]. The cross-section for prompt production of [Formula: see text] mesons relative to the prompt [Formula: see text] cross-section is measured, for the first time, to be [Formula: see text] at a centre-of-mass energy [Formula: see text] using data corresponding to an integrated luminosity of 0.7 fb[Formula: see text], and [Formula: see text] at [Formula: see text] using 2.0 fb[Formula: see text]. The uncertainties quoted are, in order, statistical, systematic, and that on the ratio of branching fractions of the [Formula: see text] and [Formula: see text] decays to the [Formula: see text] final state. In addition, the inclusive branching fraction of [Formula: see text]-hadron decays into [Formula: see text] mesons is measured, for the first time, to be [Formula: see text], where the third uncertainty includes also the uncertainty on the [Formula: see text] inclusive branching fraction from [Formula: see text]-hadron decays. The difference between the [Formula: see text] and [Formula: see text] meson masses is determined to be [Formula: see text].

Measurement of the B¯s⁰ meson lifetime in Ds⁺π⁻ decays

We present a measurement of the ratio of the B¯s⁰ meson lifetime, in the flavor-specific decay to Ds⁺π⁻, to that of the B¯⁰ meson. The pp collision data used correspond to an integrated luminosity of 1  fb(-1), collected with the LHCb detector, at a center-of-mass energy of 7 TeV. Combining our measured value of 1.010±0.010±0.008 for this ratio with the known B¯⁰ lifetime, we determine the flavor-specific B¯s⁰ lifetime to be τ(B¯s⁰ )=1.535±0.015±0.014  ps, where the uncertainties are statistical and systematic, respectively. This is the most precise measurement to date, and is consistent with previous measurements and theoretical predictions.

Observation of overlapping spin-1 and spin-3 D0K- resonances at mass 2.86 GeV/c2

The resonant substructure of B(s)(0) → D(0)K(-)π(+) decays is studied using a data sample corresponding to an integrated luminosity of 3.0 fb(-1) of pp collision data recorded by the LHCb detector. An excess at m(D(0)K(-))≈ 2.86 GeV/c(2) is found to be an admixture of spin-1 and spin-3 resonances. Therefore, the D(sJ)*(2860)(-) state previously observed in inclusive e(+)e(-) → D(0)K(-)X and pp → D(0)K(-)X processes consists of at least two particles. This is the first observation of a heavy flavored spin-3 resonance, and the first time that any spin-3 particle has been seen to be produced in B decays. The masses and widths of the new states and of the D(s2)*(2573)(-) meson are measured, giving the most precise determinations to date.

Test of lepton universality using b+ → K+ℓ+ℓ- decays

A measurement of the ratio of the branching fractions of the B(+) → K(+)μ(+)μ(-) and B(+) → K(+)e(+)e(-) decays is presented using proton-proton collision data, corresponding to an integrated luminosity of 3.0 fb(-1), recorded with the LHCb experiment at center-of-mass energies of 7 and 8 TeV. The value of the ratio of branching fractions for the dilepton invariant mass squared range 1 < q(2) < 6 GeV(2)/c(4) is measured to be 0.745(-0.074)(+0.090)(stat) ± 0.036(syst). This value is the most precise measurement of the ratio of branching fractions to date and is compatible with the standard model prediction within 2.6 standard deviations.

First observation of a baryonic Bc+ decay

A baryonic decay of the B(c)(+) meson, B(c)(+) → J/ψppπ(+), is observed for the first time, with a significance of 7.3 standard deviations, in pp collision data collected with the LHCb detector and corresponding to an integrated luminosity of 3.0 fb(-1) taken at center-of-mass energies of 7 and 8 TeV. With the B(c)(+) → J/ψπ(+) decay as the normalization channel, the ratio of branching fractions is measured to be B(B(c)(+) → J/ψppπ(+))/B(B(c)(+) → J/ψπ(+)) = 0.143(-0.034)(+0.039)(stat) ± 0.013(syst). The mass of the B(c)(+) meson is determined as M(B(c)(+) = 6274.0 ± 1.8(stat) ± 0.4(syst) MeV/c(2), using the B(c)(+) → J/ψppπ(+) channel.

Evidence for CP violation in B+ → ppK+ decays

Three-body B+ → ppK+ and B(+) → ppπ(+) decays are studied using a data sample corresponding to an integrated luminosity of 3.0 fb(-1) collected by the LHCb experiment in proton-proton collisions at center-of-mass energies of 7 and 8 TeV. Evidence of CP violation in the B(+) → ppK(+) decay is found in regions of the phase space, representing the first measurement of this kind for a final state containing baryons. Measurements of the forward-backward asymmetry of the light meson in the pp rest frame yield A(FB)(ppK(+),m(pp)<2.85 GeV/c(2)) = 0.495 ± 0.012 (stat) ± 0.007 (syst) and A(FB)(ppπ(+),m(pp) <2.85 GeV/c(2)) = -0.409 ± 0.033 (stat) ± 0.006 (syst). In addition, the branching fraction of the decay B(+) → Λ(1520)p is measured to be B(B(+) → Λ(1520)p) = (3.15 ± 0.48 (stat) ± 0.07 (syst) ± 0.26 (BF)) × 10(-7), where BF denotes the uncertainty on secondary branching fractions.

Monitoring liver macrophages using nanobodies targeting Vsig4: concanavalin A induced acute hepatitis as paradigm

Kupffer cells (KCs) are liver resident macrophages which are important for tissue homeostasis and have been implicated in immunogenic, tolerogenic and pathogenic immune reactions depending on the insult. These cells and the biomarkers they express thus represent interesting in vivo sensors for monitoring liver inflammation. In the current study, we explored whether KCs can be monitored non-invasively using single-photon-emission computed tomography (SPECT) with (99m)Tc labeled nanobodies (Nbs) targeting selected biomarkers. Nbs targeting V-set and immunoglobulin domain-containing 4 (Vsig4) or macrophage mannose receptor (MMR) accumulated in the liver of untreated mice. The liver targeting of anti-Vsig4 Nbs, but not anti-MMR Nbs, was blunted upon depletion of macrophages, highlighting specificity of anti-Vsig4 Nbs for liver macrophage imaging. Ex vivo flow cytometry and immunohistochemistry analysis confirmed that anti-Vsig4 Nbs specifically targeted KCs but no other cell types in the liver. Upon induction of acute hepatitis using concanavalin A (ConA), down-regulation of the in vivo imaging signal obtained using anti-Vsig4 Nbs reflected reduction in KC numbers and transient modulation of Vsig4 expression on KCs. Overall, these results indicate that Nbs targeting Vsig4 as molecular imaging biomarker enable non-invasive monitoring of KCs during hepatic inflammation.

MIF contributes to Trypanosoma brucei associated immunopathogenicity development

African trypanosomiasis is a chronic debilitating disease affecting the health and economic well-being of many people in developing countries. The pathogenicity associated with this disease involves a persistent inflammatory response, whereby M1-type myeloid cells, including Ly6C^high inflammatory monocytes, are centrally implicated. A comparative gene analysis between trypanosusceptible and trypanotolerant animals identified MIF (macrophage migrating inhibitory factor) as an important pathogenic candidate molecule. Using MIF-deficient mice and anti-MIF antibody treated mice, we show that MIF mediates the pathogenic inflammatory immune response and increases the recruitment of inflammatory monocytes and neutrophils to contribute to liver injury in Trypanosoma brucei infected mice. Moreover, neutrophil-derived MIF contributed more significantly than monocyte-derived MIF to increased pathogenic liver TNF production and liver injury during trypanosome infection. MIF deficient animals also featured limited anemia, coinciding with increased iron bio-availability, improved erythropoiesis and reduced RBC clearance during the chronic phase of infection. Our data suggest that MIF promotes the most prominent pathological features of experimental trypanosome infections (i.e. anemia and liver injury), and prompt considering MIF as a novel target for treatment of trypanosomiasis-associated immunopathogenicity.

Uncontrolled inflammation is a major contributor to pathogenicity development during many chronic parasitic infections, including African trypanosome infections. Hence, therapies should aim at re-establishing the balance between pro- and anti-inflammatory responses to reduce tissue damage. Our experiments uncovered that macrophage migration inhibitory factor (MIF) plays a pivotal role in trypanosomiasis-associated pathogenicity development. Hereby, MIF-deficient and neutralizing anti-MIF antibody-treated wild type (WT) T. brucei-infected mice exhibited decreased inflammatory responses, reduced liver damage and anemia (i.e. the most prominent pathogenicity features) compared to WT control mice. The reduced tissue damage coincided with reduced infiltration of pathogenic monocytic cells and neutrophils, whereby neutrophil-derived MIF contributed more significantly than monocyte-derived MIF to tissue damage. MIF also promoted anemia development by suppressing red blood cell production and enhancing their clearance. The clinical significance of these findings follows from human genetic data indicating that low-expression (protective) MIF alleles are enriched in Africans. The current findings therefore offer promise for human translation and open the possibility of assessing MIF levels or MIF genotype as an indication of an individual's risk for severe trypanosomiasis. Furthermore, given the unmet medical need of African trypanosomiasis affecting millions of people, these findings highlight MIF as a potential new therapeutic target for treatment of trypanosomiasis-associated pathogenicity.

First measurement of the charge asymmetry in beauty-quark pair production

The difference in the angular distributions between beauty quarks and antiquarks, referred to as the charge asymmetry, is measured for the first time in bb pair production at a hadron collider. The data used correspond to an integrated luminosity of 1.0 fb(-1) collected at 7 TeV center-of-mass energy in proton-proton collisions with the LHCb detector. The measurement is performed in three regions of the invariant mass of the bb system. The results obtained are A(C)(bb))(40<M(bb))<75 GeV/c(2)) = 0.4 ± 0.4 ± 0.3%, A(C)(bb))(75<M(bb)) < 105 GeV/c(2)) = 2.0 ± 0.9 ± 0.6%, A(C)(bb)(M(bb)) > 105 GeV/c(2)) = 1.6 ± 1.7 ± 0.6%, where A(C)(bb)) is defined as the asymmetry in the difference in rapidity between jets formed from the beauty quark and antiquark, where in each case the first uncertainty is statistical and the second systematic. The beauty jets are required to satisfy 2 < η < 4, E(T) >20 GeV, and have an opening angle in the transverse plane Δ ϕ > 2.6 rad. These measurements are consistent with the predictions of the standard model.

Precision measurement of the mass and lifetime of the Ξ(b)(0) baryon

Using a proton-proton collision data sample corresponding to an integrated luminosity of 3 fb(-1) collected by LHCb at center-of-mass energies of 7 and 8 TeV, about 3800 Ξ(b)(0) → Ξ(c)(+)π(-), Ξ(c)(+)) → pK(-)π(+) signal decays are reconstructed. From this sample, the first measurement of the Ξ(b)(0) baryon lifetime is made, relative to that of the Λ(b)(0) baryon. The mass differences M(Ξ(b)(0))-M(Λ(b)(0)) and M(Ξ(c)(+))-M(Λ(c)(+)) are also measured with precision more than 4 times better than the current world averages. The resulting values are τ(Ξ(b)(0))/τ(Λ)(b)(0)) = 1.006 ± 0.018 ± 0.010,M(Ξ(b)(0))-M(Λ(b)(0)) = 172.44 ± 0.39 ± 0.17 MeV/c(2),M(Ξ(c)(+))-M(Λ(c)(+)) = 181.51 ± 0.14 ± 0.10 MeV/c(2),where the first uncertainty is statistical and the second is systematic. The relative rate of Ξ(b)(0) to Λ(b)(0) baryon production is measured to be f(Ξ)(b)(0))/f(Λ)(b)(0))B(Ξ(b)(0) → Ξ(c)(+)π(-))/B(Λ(b)(0) → Λ(c)(+)π(-))B(Ξ(c)(+) → pK(-)π(+))/B(Λ(c)(+) → pK(-)}π(+)) = (1.88 ± 0.04 ± 0.03) × 10(-2),where the first factor is the ratio of fragmentation fractions, b → Ξ(b)(0) relative to b → Λ(b)(0). Relative production rates as functions of transverse momentum and pseudorapidity are also presented.

Observation of the resonant character of the Z(4430)(-) state

Resonant structures in B^{0}→ψ^{'}π^{-}K^{+} decays are analyzed by performing a four-dimensional fit of the decay amplitude, using pp collision data corresponding to 3  fb^{-1} collected with the LHCb detector. The data cannot be described with K^{+}π^{-} resonances alone, which is confirmed with a model-independent approach. A highly significant Z(4430)^{-}→ψ^{'}π^{-} component is required, thus confirming the existence of this state. The observed evolution of the Z(4430)^{-} amplitude with the ψ^{'}π^{-} mass establishes the resonant nature of this particle. The mass and width measurements are substantially improved. The spin parity is determined unambiguously to be 1^{+}.

Measurement of charged particle multiplicities and densities in [Formula: see text] collisions at [Formula: see text]TeV in the forward region

Charged particle multiplicities are studied in proton-proton collisions in the forward region at a centre-of-mass energy of [Formula: see text]TeV with data collected by the LHCb detector. The forward spectrometer allows access to a kinematic range of [Formula: see text] in pseudorapidity, momenta greater than [Formula: see text] and transverse momenta greater than [Formula: see text]. The measurements are performed using events with at least one charged particle in the kinematic acceptance. The results are presented as functions of pseudorapidity and transverse momentum and are compared to predictions from several Monte Carlo event generators.

Measurement of [Formula: see text] polarisation in [Formula: see text] collisions at [Formula: see text] = 7 TeV

The polarisation of prompt [Formula: see text] mesons is measured by performing an angular analysis of [Formula: see text] decays using proton-proton collision data, corresponding to an integrated luminosity of 1.0[Formula: see text], collected by the LHCb detector at a centre-of-mass energy of 7 TeV. The polarisation is measured in bins of transverse momentum [Formula: see text] and rapidity [Formula: see text] in the kinematic region [Formula: see text] and [Formula: see text], and is compared to theoretical models. No significant polarisation is observed.

Measurement of the [Formula: see text] meson lifetime using [Formula: see text] decays

The lifetime of the [Formula: see text] meson is measured using semileptonic decays having a [Formula: see text] meson and a muon in the final state. The data, corresponding to an integrated luminosity of [Formula: see text], are collected by the LHCb detector in [Formula: see text] collisions at a centre-of-mass energy of 8 TeV. The measured lifetime is [Formula: see text]where the first uncertainty is statistical and the second is systematic.

Observation of photon polarization in the b→sγ transition

This Letter presents a study of the flavor-changing neutral current radiative B±→K±π∓π±γ decays performed using data collected in proton-proton collisions with the LHCb detector at 7 and 8 TeV center-of-mass energies. In this sample, corresponding to an integrated luminosity of 3  fb-1, nearly 14 000 signal events are reconstructed and selected, containing all possible intermediate resonances with a K±π∓π± final state in the [1.1,1.9]  GeV/c2 mass range. The distribution of the angle of the photon direction with respect to the plane defined by the final-state hadrons in their rest frame is studied in intervals of K±π∓π± mass and the asymmetry between the number of signal events found on each side of the plane is obtained. The first direct observation of the photon polarization in the b→sγ transition is reported with a significance of 5.2σ.

Search for Majorana neutrinos in B- → π+ μ- μ- decays

A search for heavy Majorana neutrinos produced in the B- → π+ μ- μ- decay mode is performed using 3  fb(-1) of integrated luminosity collected with the LHCb detector in pp collisions at center-of-mass energies of 7 and 8 TeV at the LHC. Neutrinos with masses in the range 250 to 5000 MeV and lifetimes from zero to 1000 ps are probed. In the absence of a signal, upper limits are set on the branching fraction B(B- → π+ μ- μ-) as functions of neutrino mass and lifetime. These limits are on the order of 10(-9) for short neutrino lifetimes of 1 ps or less. Limits are also set on the coupling between the muon and a possible fourth-generation neutrino.

Measurement of the Bs(0) → Ds-Ds+ and Bs(0) → D-Ds+ effective lifetimes

The first measurement of the effective lifetime of the B(s)(0) meson in the decay B(s)(0) → Ds-Ds+ is reported using a proton-proton collision data set, corresponding to an integrated luminosity of 3 fb(-1), collected by the LHCb experiment. The measured value of the B(s)(0) → Ds-Ds+ effective lifetime is 1.379 ± 0.026 ± 0.017 ps, where the uncertainties are statistical and systematic, respectively. This lifetime translates into a measurement of the decay width of the light B(s)(0) mass eigenstate of ΓL = 0.725 ± 0.014 ± 0.009 ps(-1). The B(s)(0) lifetime is also measured using the flavor-specific B(s)(0)→ D-Ds+ decay to be 1.52 ± 0.15 ± 0.01 ps.

Observation of B(s)(0) → J/ψ f1(1285) decays and measurement of the f1(1285) mixing angle

Decays of B(s)(0) and B(0) mesons into J/ψ π+π-π+π- final states, produced in pp collisions at the LHC, are investigated using data corresponding to an integrated luminosity of 3 fb-1 collected with the LHCb detector. B(s)(0) → J/ψ f1(1285) decays are seen for the first time, and the branching fractions are measured. Using these rates, the f1(1285) mixing angle between strange and nonstrange components of its wave function in the qq structure model is determined to be ±(24.0-2.6-0.8+3.1+0.6)°. Implications on the possible tetraquark nature of the f1(1285) are discussed.

Measurements of indirect CP asymmetries in D0 → K- K+ and D0 → π- π+ decays

A study of indirect CP violation in D0 mesons through the determination of the parameter AΓ is presented using a data sample of pp collisions, corresponding to an integrated luminosity of 1.0  fb(-1), collected with the LHCb detector and recorded at the center-of-mass energy of 7 TeV at the LHC. The parameter AΓ is the asymmetry of the effective lifetimes measured in decays of D0 and D0 mesons to the CP eigenstates K- K+ and π- π+. Fits to the data sample yield AΓ(KK)=(-0.35±0.62±0.12)×10(-3) and AΓ(ππ)=(0.33±1.06±0.14)×10(-3), where the first uncertainties are statistical and the second systematic. The results represent the world's best measurements of these quantities. They show no difference in AΓ between the two final states and no indication of CP violation.

Measurement of CP violation in the phase space of B± → K+ K- π± and B± → π+ π- π± decays

The charmless decays B± → K+ K- π± and B± → π+ π- π± are reconstructed in a data set of pp collisions with an integrated luminosity of 1.0  fb(-1) and center-of-mass energy of 7 TeV, collected by LHCb in 2011. The inclusive charge asymmetries of these modes are measured to be A(CP)(B± → K+ K- π±) = -0.141±0.040  (stat)±0.018 (syst)±0.007(J/ψ K±) and A(CP)(B± → π+ π- π±) = 0.117±0.021 (stat)±0.009 (syst)±0.007(J/ψ K±), where the third uncertainty is due to the CP asymmetry of the B± → J/ψK± reference mode. In addition to the inclusive CP asymmetries, larger asymmetries are observed in localized regions of phase space.

Measurement of D0-D0 mixing parameters and search for CP violation using D0 → K+ π- decays

Measurements of charm mixing parameters from the decay-time-dependent ratio of D0 → K+ π- to D0 → K- π+ rates and the charge-conjugate ratio are reported. The analysis uses data, corresponding to 3  fb(-1) of integrated luminosity, from proton-proton collisions at 7 and 8 TeV center-of-mass energies recorded by the LHCb experiment. In the limit of charge-parity (CP ) symmetry, the mixing parameters are determined to be x'2=(5.5±4.9)×10(-5), y'=(4.8±1.0)×10(-3), and RD=(3.568±0.066)×10(-3). Allowing for CP violation, the measurement is performed separately for D0 and D0 mesons yielding AD=(-0.7±1.9)%, for the direct CP-violating asymmetry, and 0.75<|q/p|<1.24 at the 68.3% confidence level, for the parameter describing CP violation in mixing. This is the most precise determination of these parameters from a single experiment and shows no evidence for CP violation.

Measurement of J/ψ polarization in pp collisions at [Formula: see text]

An angular analysis of the decay J/ψ→μ+μ- is performed to measure the polarization of prompt J/ψ mesons produced in pp collisions at [Formula: see text]. The dataset corresponds to an integrated luminosity of 0.37 fb-1 collected with the LHCb detector. The measurement is presented as a function of transverse momentum, pT, and rapidity, y, of the J/ψ meson, in the kinematic region 2 Collapse

Key Words Collapse

MESH Headings Collapse

Grants Collapse

Measurement of form-factor-independent observables in the decay B0→K(*0)μ(+)μ(-)

We present a measurement of form-factor-independent angular observables in the decay B(0)→K*(892)(0)μ(+)μ(-). The analysis is based on a data sample corresponding to an integrated luminosity of 1.0 fb(-1), collected by the LHCb experiment in pp collisions at a center-of-mass energy of 7 TeV. Four observables are measured in six bins of the dimuon invariant mass squared q² in the range 0.1<q²<19.0 GeV²/c(4). Agreement with recent theoretical predictions of the standard model is found for 23 of the 24 measurements. A local discrepancy, corresponding to 3.7 Gaussian standard deviations is observed in one q² bin for one of the observables. Considering the 24 measurements as independent, the probability to observe such a discrepancy, or larger, in one is 0.5%.

Observation of the decay B(c)(+) → B(s)(0)π+

The result of a search for the decay B(c)(+) → B(s)(0) π+ is presented, using the B(s)(0) → D(s)(-)π+ and B(s)(0) → J/ψ Ø channels. The analysis is based on a data sample of pp collisions collected with the LHCb detector, corresponding to an integrated luminosity of 1 fb(-1) taken at a center-of-mass energy of 7 TeV, and 2 fb(-1) taken at 8 TeV. The decay B(c)(+) → B(s)(0)π+ is observed with significance in excess of 5 standard deviations independently in both decay channels. The measured product of the ratio of cross sections and branching fraction is [σ(B(c)(+))/σ(B(s)(0))] × B(B(c)(+)→ B(s)(0)π+) = [2.37 ± 0.31 (stat)± 0.11 (syst)(-0.13)(+0.17)(τ(B)(c)(+)))] × 10(-3), in the pseudorapidity range 2<η(B)<5, where the first uncertainty is statistical, the second is systematic, and the third is due to the uncertainty on the B(c)(+) lifetime. This is the first observation of a B meson decaying to another B meson via the weak interaction.

Measurement of the CP asymmetry in B(+)→K(+)μ(+)μ(-) decays

A measurement of the CP asymmetry in B(+)→K(+)μ(+)μ(-) decays is presented using pp collision data, corresponding to an integrated luminosity of 1.0 fb(-1), recorded by the LHCb experiment during 2011 at a center-of-mass energy of 7 TeV. The measurement is performed in seven bins of μ(+)μ(-) invariant mass squared in the range 0.05<q2<22.00 GeV2/c4, excluding the J/ψ and ψ(2S) resonance regions. Production and detection asymmetries are corrected for using the B(+)→J/ψK(+) decay as a control mode. Averaged over all the bins, the CP asymmetry is found to be A(CP)=0.000±0.033 (stat)±0.005 (syst)±0.007 (J/ψK), where the third uncertainty is due to the CP asymmetry of the control mode. This is consistent with the standard model prediction.

Search for the lepton-flavor-violating decays B(s)0→e(±)μ(∓) and B0→e(±)μ(∓)

A search for the lepton-flavor-violating decays B(s)0→e(±)μ(∓) and B0→e(±)μ(∓) is performed with a data sample, corresponding to an integrated luminosity of 1.0 fb(-1) of pp collisions at √s=7 TeV, collected by the LHCb experiment. The observed number of B(s)0→e(±)μ(∓) and B0→e(±)μ(∓) candidates is consistent with background expectations. Upper limits on the branching fractions of both decays are determined to be B(B(s)0→e(±)μ(∓))<1.1(1.4)×10(-8) and B(B0→e(±)μ(∓))<2.8(3.7)×10(-9) at 90% (95%) confidence level (C.L.). These limits are a factor of 20 lower than those set by previous experiments. Lower bounds on the Pati-Salam leptoquark masses are also calculated, M(LQ)(B(s)0→e(±)μ(∓))>101 TeV/c(2) and M(LQ)(B0→e(±)μ(∓))>126 TeV/c(2) at 95% C.L., and are a factor of 2 higher than the previous bounds.

Observation of a resonance in B+ → K+ μ+ μ- decays at low recoil

A broad peaking structure is observed in the dimuon spectrum of B+ → K+ μ+ μ- decays in the kinematic region where the kaon has a low recoil against the dimuon system. The structure is consistent with interference between the B+ → K+ μ+ μ- decay and a resonance and has a statistical significance exceeding six standard deviations. The mean and width of the resonance are measured to be 4191(-8)(+9)  MeV/c2 and 65(-16)(+22)  MeV/c2, respectively, where the uncertainties include statistical and systematic contributions. These measurements are compatible with the properties of the ψ(4160) meson. First observations of both the decay B+ → ψ(4160)K+ and the subsequent decay ψ(4160) → μ+ μ- are reported. The resonant decay and the interference contribution make up 20% of the yield for dimuon masses above 3770  MeV/c2. This contribution is larger than theoretical estimates.

Precision measurement of the Λb(0) baryon lifetime

The ratio of the Λb(0) baryon lifetime to that of the B(0) meson is measured using 1.0  fb(-1) of integrated luminosity in 7 TeV center-of-mass energy pp collisions at the LHC. The Λb(0) baryon is observed for the first time in the decay mode Λb(0)→J/ψpK-, while the B(0) meson decay used is the well known B(0)→J/ψπ+ K- mode, where the π+ K- mass is consistent with that of the K(*0)(892) meson. The ratio of lifetimes is measured to be 0.976±0.012±0.006, in agreement with theoretical expectations based on the heavy quark expansion. Using previous determinations of the B(0) meson lifetime, the Λb(0) lifetime is found to be 1.482±0.018±0.012  ps. In both cases, the first uncertainty is statistical and the second systematic.

Measurement of CP violation in the phase space of B±→K± π+ π- and B±→K± K+ K- decays

The charmless decays B±→K± π+ π- and B±→K± K+ K- are reconstructed using data, corresponding to an integrated luminosity of 1.0  fb(-1), collected by LHCb in 2011. The inclusive charge asymmetries of these modes are measured as ACP(B±→K± π+ π-)=0.032±0.008 (stat)±0.004 (syst)±0.007(J/ψK±) and ACP(B±→K± K+ K-)=-0.043±0.009 (stat)±0.003 (syst)±0.007(J/ψK±), where the third uncertainty is due to the CP asymmetry of the B±→J/ψK± reference mode. The significance of ACP(B±→K± K+ K-) exceeds three standard deviations and is the first evidence of an inclusive CP asymmetry in charmless three-body B decays. In addition to the inclusive CP asymmetries, larger asymmetries are observed in localized regions of phase space.

Measurement of the Bs(0)→μ+ μ- branching fraction and search for B(0)→μ+ μ- decays at the LHCb experiment

A search for the rare decays Bs(0)→μ+ μ- and B(0)→μ+ μ- is performed at the LHCb experiment. The data analyzed correspond to an integrated luminosity of 1  fb(-1) of pp collisions at a center-of-mass energy of 7 TeV and 2  fb(-1) at 8 TeV. An excess of Bs(0)→μ+ μ- signal candidates with respect to the background expectation is seen with a significance of 4.0 standard deviations. A time-integrated branching fraction of B(Bs(0)→μ+ μ-)=(2.9(-1.0)(+1.1))×10(-9) is obtained and an upper limit of B(B(0)→μ+ μ-)<7.4×10(-10) at 95% confidence level is set. These results are consistent with the standard model expectations.

First measurement of the CP-violating phase in Bs(0) → ϕϕ decays

A first flavor-tagged measurement of the time-dependent CP-violating asymmetry in B(s)(0) → ϕϕ decays is presented. In this decay channel, the CP-violating weak phase arises due to CP violation in the interference between B(s)(0)-B(s)(0) mixing and the b → sss gluonic penguin decay amplitude. Using a sample of pp collision data corresponding to an integrated luminosity of 1.0 fb(-1) and collected at a center-of-mass energy of 7 TeV with the LHCb detector, 880 B(s)(0) → ϕϕ signal decays are obtained. The CP-violating phase is measured to be in the interval [-2.46,-0.76] rad at a 68% confidence level. The p value of the standard model prediction is 16%.

Measurements of the branching fractions of [Formula: see text] decays

The branching fractions of the decay [Formula: see text] for different intermediate states are measured using data, corresponding to an integrated luminosity of 1.0 fb^-1, collected by the LHCb experiment. The total branching fraction, its charmless component [Formula: see text] and the branching fractions via the resonant [Formula: see text] states η_c (1S) and ψ(2S) relative to the decay via a J/ψ intermediate state are [Formula: see text] Upper limits on the B⁺ branching fractions into the η_c (2S) meson and into the charmonium-like states X(3872) and X(3915) are also obtained.

First observation of CP violation in the decays of B(s)0 mesons

Using pp collision data corresponding to an integrated luminosity of 1.0 fb(-1) and collected by LHCb in 2011 at a center-of-mass energy of 7 TeV, we report the measurement of direct CP violation in B(s)(0)→K(-)π(+) decays, A(CP)(B(s)(0)→K(-)π(+)=0.27±0.04 (stat)±0.01 (syst), with significance exceeding 5 standard deviations. This is the first observation of CP violation in the decays of B(s)(0) mesons. Furthermore, we provide an improved determination of direct CP violation in B(0)→K(+)π(-) decays, A(CP)(B(0)→K(+)π(-)=-0.080±0.007 (stat)±0.003 (syst), which is the most precise measurement of this quantity to date.

Determination of the X(3872) meson quantum numbers

The quantum numbers of the X(3872) meson are determined to be J(PC)=1(++) based on angular correlations in B(+)→X(3872)K(+) decays, where X(3872)→π(+)π(-)J/ψ and J/ψ→μ(+)μ(-). The data correspond to 1.0 fb(-1) of pp collisions collected by the LHCb detector. The only alternative assignment allowed by previous measurements J(PC)=2(-+) is rejected with a confidence level equivalent to more than 8 Gaussian standard deviations using a likelihood-ratio test in the full angular phase space. This result favors exotic explanations of the X(3872) state.

Search for rare B(0)((s))→μ(+)μ(-)μ(+)μ(-) decays

A search for the decays B(0)((s))→μ(+)μ(-)μ(+)μ(-) and B(0)→μ(+)μ(-)μ(+)μ(-) is performed using data, corresponding to an integrated luminosity of 1.0 fb(-1), collected with the LHCb detector in 2011. The number of candidates observed is consistent with the expected background and, assuming phase-space models of the decays, limits on the branching fractions are set: B(B(s)(0)→μ(+)μ(-)μ(+)μ(-))<1.6(1.2)×10(-8) and B(B(0)→μ(+)μ(-)μ(+)μ(-))<6.6(5.3)×10(-9) at 95% (90%) confidence level. In addition, limits are set in the context of a supersymmetric model which allows for the B((s))(0) meson to decay into a scalar (S) and pseudoscalar particle (P), where S and P have masses of 2.5 GeV/c and 214.3 MeV/c, respectively, both resonances decay into μ(+)μ(-). The branching fraction limits for these decays are B(B(s)(0)→SP)<1.6(1.2)×10(-8) and B(B(0)→SP)<6.3(5.1)×10(-9) at 95% (90%) confidence level.

Measurement of the forward energy flow in pp collisions at [Formula: see text]

The energy flow created in pp collisions at [Formula: see text] is studied within the pseudorapidity range 1.9<η<4.9 with data collected by the LHCb experiment. The measurements are performed for inclusive minimum-bias interactions, hard scattering processes and events with an enhanced or suppressed diffractive contribution. The results are compared to predictions given by Pythia-based and cosmic-ray event generators, which provide different models of soft hadronic interactions.

Performance of the LHCb RICH detector at the LHC

The LHCb experiment has been taking data at the Large Hadron Collider (LHC) at CERN since the end of 2009. One of its key detector components is the Ring-Imaging Cherenkov (RICH) system. This provides charged particle identification over a wide momentum range, from 2-100 GeV/c. The operation and control, software, and online monitoring of the RICH system are described. The particle identification performance is presented, as measured using data from the LHC. Excellent separation of hadronic particle types (π, K, p) is achieved.